Intellect Neurosciences Inc. (fka ILNS)

[buckiii2]

Scooped by Krishan Maggon
Scoop.it!
Pfizer silence Bapineuzumab despite Revival of beta amyloid targeting mabs

Pfizer silence Bapineuzumab despite Revival of beta amyloid targeting mabs | Alzheimer's Disease R&D Review | Scoop.it
Today, 12:45 PM
AAIC 2015 was a revival of monoclonal antibodies targeting beta amyloid plaques led by Biogen Aducanumab, Lilly solanezumab and Roche Gantenerumab and crenezumab. These mabs were effective in preventing growth of amyloid plaques in early onset Alzheimer's disease.
Krishan Maggon 's insight:
Lilly and Roche have reactivated their failed monoclonal antibodies to concentrate on the early onset Alzheimer's disease and show reduction of amyloid plaques FDA new surrogate end point for efficacy.

The first in the class amyloid plaques targeting mab Bapineuzumab from Pfizer is absent from this revival?

Pfizer should tell AD patients and its investors why Bapineuzumab is not reactivated?